Ticker Symbol: GTHX
G1 Therapeutics Inc
$14.25 - 02-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001560241
Company Profile
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 700 Park Offices Drive
Website: www.g1therapeutics.com
CEO: Mark Velleca
Tags:
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $1.26
Change:
-$0.10
(
-7.35%)
Days Range: $1.24 - $1.35
Beta: 1.54
52wk. High: $11.78
52wk. Low: $1.08
Ytd. Change -82.31%
50 Day Moving Average: $1.37
200 Day Moving Average: $2.21
Shares Outstanding: 51745578
Valuation
Market Cap: 6.5B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A